NCT07471763Not yet recruiting
Prospective Lifespan Cohort of Myocardial Infarction
A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System
Source: ClinicalTrials.gov · Last updated 25 Mar 2026
Brief summary (registry, in English)
This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management. The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up. The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 6000 (estimated)
- First submitted
- 10 Mar 2026
- Start date
- 10 Apr 2026
- Primary completion date
- 10 Apr 2031
- Lead sponsor
- Fujian Provincial Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07471763
What you commit to
- Study type: Observational
- Planned participants: 6000
- From 10 Apr 2026 to the primary completion date, 10 Apr 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous participation in another clinical study that may conflict with this project
Other illness
- End-stage malignant tumor with expected survival of less than 1 year
- Active autoimmune disease or long-term use of immunosuppressive agents
- Inability to provide informed consent or severe cognitive impairment
- Any other condition considered by the investigators to make participation inappropriate
Other
- Severe hepatic or renal dysfunction (estimated glomerular filtration rate \<30 mL/min/1.73 m² or Child-Pugh class C)
- Pregnant or breastfeeding women
Who the study is looking for
- Age 18 to 74 years
- Diagnosed with stable angina, unstable angina, or acute myocardial infarction
- For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized
- Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction
- Willing to participate and able to provide written informed consent
- Able to complete baseline assessment, biospecimen collection, and long-term follow-up
Age in the registry: 18 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuzhou University Affiliated Provincial Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.